Clinical Effectiveness of Pre-operative Methadone in Single Level Lateral Transpsoas Interbody Fusions

NCT ID: NCT04112550

Last Updated: 2020-01-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-02-11
• Study Completion Date: 2021-12-31

Brief Summary

Spinal operations including lumbar fusions for degenerative disorders are becoming more prevalent as the population ages. Inadequate or excessive postoperative analgesia can result in medical comorbidities and prolonged hospital length of stay and patient dissatisfaction.

Existing literature has highlighted the preoperative administration of methadone as a promising adjuvant for post operative pain control. Methadone has the benefit of being long-acting and has more stable serum concentration and a single preoperative dose may have significant benefits post operatively.

Here the investigators propose a prospective parallel-group, randomized, double-blinded study to assess post operative analgesic requirements after preoperative administration of either methadone 15 mg or Oxycodone 10/325. Primary outcome will be total IV and PO narcotic consumption in the post operative course. Secondary outcomes examined will include time to mobility, need for specialist pain management consultation, early readmission (within 2 weeks) for inadequate pain control, and complications associated with administration.

Detailed Description

Lumbar spinal fusions are becoming increasingly popular and prevalent in the treatment of a variety of spinal pathologies, but predominantly for degenerative disease which is most prevalent in the obese and or older population. These operations can result in relatively high post operative surgical pain and necessitate significant post operative opioid consumption which can precipitate co-morbid medical conditions such as respiratory depression and failure, pneumonia, gastrointestinal ileus, deep venous thrombosis, and pulmonary embolism. Additionally, these medical comorbidities also represent an increased burden on healthcare expenditure with increased length of hospital stay, inpatient testing and treatment, and need for additional follow up.

The investigators objective is to study the effect of a long term opioid analgesic, methadone, in a uniform population undergoing a single level minimally invasive lumbar fusion. The preoperative single dose administration of methadone has already been shown to be effective in improving post operative pain control in open multi-level spinal fusion patient populations and has become the standard of care in most surgical centers across the country. The long half-life of methadone results in improved steady state pharmacokinetics relative to other traditional opioids and is thought to improve pain control while decreasing consumption. In addition to Mu opioid receptor agonism, Methadone is thought to also have adjunctive analgesic and anti-tolerance effects due to CNS excitatory glutamatergic NMDA receptor antagonism. There are also reports of synergistic effects from serotonin and norepinephrine reuptake inhibition.

The investigators predict that a single preoperative oral methadone administration can result in improved postoperative analgesia with requirement of less IV and PO traditional narcotics within the first 2 weeks post operatively and also will not increase co-morbid risks relative to traditional shorter acting opioid analgesics that are presently given preoperatively.

Conditions

Degenerative Disc Disease; Spondylolisthesis, Lumbar Region

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Methadone

This cohort will receive oral methadone 15mg po tablet pre-operatively

Group Type: ACTIVE_COMPARATOR

Methadone Hydrochloride

Intervention Type: DRUG

FDA approved medication to treat pain

Oxycodone

This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively

Group Type: ACTIVE_COMPARATOR

Oxycodone-Acetaminophen

Intervention Type: DRUG

FDA approved medication to treat pain

Interventions

Methadone Hydrochloride

FDA approved medication to treat pain

Intervention Type: DRUG

Oxycodone-Acetaminophen

FDA approved medication to treat pain

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age: 18 - 70
• Will undergo one level minimally invasive lumbar fusion surgery
• Primary symptoms are back and/or leg pain

Exclusion Criteria

• Preoperative chronic renal insufficiency or failure (defined as a serum creatinine more than 2 mg/dl)
• Significant liver disease (cirrhosis or hepatic failure)
• American Society of Anesthesiologists (ASA) physical status IV or V
• Pulmonary disease necessitating home oxygen therapy
• Patients with acute bronchial asthma or hypercarbia
• Patient who has or is suspected of having a paralytic ileus
• Preoperative use of methadone or hydromorphone
• Known hypersensitivity to methadone
• Known hypersensitivity to oxycodone
• Recent history of opioid or alcohol abuse
• Inability to use a PCA device
• Inability to speak English
• Any patient judged by the anesthesia care team to potentially require prolonged postoperative intubation
• Participation in another clinical trial
• Inability of patient to provide study informed consent (including patients who are cognitively impaired)
• Presence of drug interaction between methadone/oxycodone and patient's regular or PRN medications

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

The Methodist Hospital Research Institute

OTHER

Sponsor Role: lead

Responsible Party

SBarber

Neurosurgery Faculty

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sean M Barber, MD

Role: PRINCIPAL_INVESTIGATOR

The Methodist Hospital Research Institute

Central Contacts

Saeed S Sadrameli, MD, MS

Role: CONTACT

ssadrameli@houstonmethodist.org

2817431385

Marcus S Wong, MD

Role: CONTACT

mswong@houstonmethodist.org

8324574452

Other Identifiers

Pro00022567

Identifier Type: -

Identifier Source: org_study_id